These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31401535)

  • 1. Discovery of β-carboline copper(II) complexes as Mcl-1 inhibitor and in vitro and in vivo activity in cancer models.
    Lu X; Liu YC; Orvig C; Liang H; Chen ZF
    Eur J Med Chem; 2019 Nov; 181():111567. PubMed ID: 31401535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent.
    Lu X; Liu YC; Orvig C; Liang H; Chen ZF
    J Med Chem; 2020 Sep; 63(17):9154-9167. PubMed ID: 32794745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
    Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD; Gregory GP; Hargreaves D; Hendricks JA; Johannes JW; Johnstone RW; Kazmirski SL; Kettle JG; Lamb ML; Matulis SM; Nooka AK; Packer MJ; Peng B; Rawlins PB; Robbins DW; Schuller AG; Su N; Yang W; Ye Q; Zheng X; Secrist JP; Clark EA; Wilson DM; Fawell SE; Hird AW
    Nat Commun; 2018 Dec; 9(1):5341. PubMed ID: 30559424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lasing the DNA fragments through β-diketimine framed Knoevenagel condensed Cu(II) and Zn(II) complexes--an in vitro and in vivo approach.
    Raman N; Pravin N
    Spectrochim Acta A Mol Biomol Spectrosc; 2014 Jan; 118():867-82. PubMed ID: 24161850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel copper complexes as potential proteasome inhibitors for cancer treatment (Review).
    Zhang Z; Wang H; Yan M; Wang H; Zhang C
    Mol Med Rep; 2017 Jan; 15(1):3-11. PubMed ID: 27959411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo anti-proliferative evaluation of bis(4'-(4-tolyl)-2,2':6',2″-terpyridine)copper(II) complex against Ehrlich ascites carcinoma tumors.
    Mahendiran D; Kumar RS; Viswanathan V; Velmurugan D; Rahiman AK
    J Biol Inorg Chem; 2017 Oct; 22(7):1109-1122. PubMed ID: 28884428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive overview of β-carbolines and its derivatives as anticancer agents.
    Luo B; Song X
    Eur J Med Chem; 2021 Nov; 224():113688. PubMed ID: 34332400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
    Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
    Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed-ligand Cu(II) hydrazone complexes designed to enhance anticancer activity.
    Mo Q; Deng J; Liu Y; Huang G; Li Z; Yu P; Gou Y; Yang F
    Eur J Med Chem; 2018 Aug; 156():368-380. PubMed ID: 30015073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
    Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
    Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of synthetic three copper(II) complexes with terpyridine ligands.
    Yang Y; Guo FF; Chen CF; Li YL; Liang H; Chen ZF
    J Inorg Biochem; 2023 Mar; 240():112093. PubMed ID: 36525715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of Rhodium(III) complexes with 2(1H)-quinolinone derivatives and evaluation of their in vitro and in vivo antitumor activity.
    Lu X; Wu YM; Yang JM; Ma FE; Li LP; Chen S; Zhang Y; Ni QL; Pan YM; Hong X; Peng Y
    Eur J Med Chem; 2018 May; 151():226-236. PubMed ID: 29614419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Mcl-1 inhibitors for cancer therapy.
    Negi A; Murphy PV
    Eur J Med Chem; 2021 Jan; 210():113038. PubMed ID: 33333396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrrolo [3,4-
    Wang D; Nie Z; Jiang X; Ye J; Wei Z; Cheng D; Wang C; Wu Y; Liu R; Chen H; Chen C; Wang C
    Aging (Albany NY); 2020 May; 12(10):9621-9632. PubMed ID: 32452831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
    Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
    J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
    Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
    J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New 3-tetrazolyl-β-carbolines and β-carboline-3-carboxylates with anti-cancer activity.
    Panice MR; Lopes SMM; Figueiredo MC; Goes Ruiz ALT; Foglio MA; Nazari Formagio AS; Sarragiotto MH; Pinho E Melo TMVD
    Eur J Med Chem; 2019 Oct; 179():123-132. PubMed ID: 31247374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule Mcl-1 inhibitors for the treatment of cancer.
    Belmar J; Fesik SW
    Pharmacol Ther; 2015 Jan; 145():76-84. PubMed ID: 25172548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
    Wan Y; Liu T; Li X; Chen C; Fang H
    Bioorg Med Chem; 2017 Jan; 25(1):138-152. PubMed ID: 27810438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCL-1 inhibitors - where are we now (2019)?
    Fletcher S
    Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.